Tradestie Institutional Equity Comparison Engine
MPLT vs CRMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin, Momentum & Technical while MPLT counters with relative strength in Options & Structure. Fundamentally, MPLT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CRMD at 49.0x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, MPLT sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
MPLT N/M vs CRMD 49.0x Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 0.0% vs 41.0% ยท YoY +0.0% vs -47.7%
Momentum & Technical Winner
CRMD
1Y -51.4% vs -56.2% ยท 52W Pos 3% vs 3%
Options & Structure Winner
MPLT
BREAKDOWN (8th %ile IV) vs BREAKDOWN (25th %ile IV)
MPLT
US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap
$392.9M
1M Return
-9.87%
1Y Return
-51.4%
Forward P/E
N/M
Unified AI Score
50.4 / 100
HOLD
Tech 49.0
Fund 56.0
Flow 64.0
Mom 58.9
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap
$384.7M
1M Return
-32.3%
1Y Return
-56.16%
Forward P/E
49.0x
Unified AI Score
53.2 / 100
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MPLT -51.4%
CRMD -56.16%
Spread: +4.76 pp (MPLT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MPLT TTM Op. Margin: 0.0%
CRMD TTM Op. Margin: 41.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPLT vs CRMD. Trailing 12-month operating profitability (MPLT 0.0% vs CRMD 41.0%) and valuation multiples (MPLT N/M vs CRMD 49.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MPLT | CRMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $392.9M | $384.7M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | 2.4x | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | N/M | 49.0x | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | +0.0% | -47.7% | Higher Growth | MPLT |
| Operating Margin (TTM) Profitability | 0.0% | 41.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 0.0% | 15.5% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | -111.5% | 15.3% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 3% ($6โ$40) | 3% ($5โ$13) | Stronger Trend | CRMD |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 78% Vol | 1.20ฮฒ ยท 107% Vol | Lower Realized Risk | MPLT |
| Unified Institutional Score Composite Signal | 50.4 / 100 (HOLD) | 53.2 / 100 (HOLD) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MPLT vs CRMD Buy Guide
MPLT
BREAKDOWN
144d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
CRMD
BREAKDOWN
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MPLT nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.